Shepherd Kaplan Krochuk’s Neurocrine Biosciences NBIX Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,094	Closed	-$318K	–	268
2017 Q4	$318K	Sell	4,094 -4,075	-50%	-$278K	0.2%	137
2017 Q3	$501K	Hold	8,169	–	–	0.42%	77
2017 Q2	$376K	Hold	8,169	–	–	0.22%	104
2017 Q1	$354K	Buy	8,169 +2,880	+54%	+$123K	0.18%	109
2016 Q4	$205K	Sell	5,289 -4,054	-43%	-$184K	0.06%	170
2016 Q3	$473K	Hold	9,343	–	–	0.1%	144
2016 Q2	$425K	Hold	9,343	–	–	0.11%	132
2016 Q1	$370K	Sell	9,343 -3,114	-25%	-$124K	0.11%	128
2015 Q4	$705K	Sell	12,457 -17,211	-58%	-$875K	0.19%	81
2015 Q3	$1.18M	Sell	29,668 -5,770	-16%	-$279K	0.31%	51
2015 Q2	$1.69M	Hold	35,438	–	–	0.32%	51
2015 Q1	$1.41M	Sell	35,438 -25,260	-42%	-$904K	0.25%	70
2014 Q4	$1.36M	Hold	60,698	–	–	0.22%	95
2014 Q3	$951K	Buy	60,698 +6,910	+13%	+$103K	0.12%	143
2014 Q2	$798K	Buy	53,788 +26,117	+94%	+$369K	0.08%	164
2014 Q1	$446K	Hold	27,671	–	–	0.05%	226
2013 Q4	$258K	Hold	27,671	–	–	0.03%	372
2013 Q3	$313K	Hold	27,671	–	–	0.05%	281
2013 Q2	$370K	Buy	+27,671	New	+$340K	0.07%	244

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Shepherd Kaplan Krochuk's NBIX Position: Q1 2018 in Review

Shepherd Kaplan Krochuk sold out of Neurocrine Biosciences (NBIX) in Q1 2018, closing a stake of 4,094 shares — an estimated $318K sold.

Shepherd Kaplan Krochuk first reported a position in NBIX in Q2 2013 and held it in 19 quarters. The position peaked at $1.69M in Q2 2015. 267 funds tracked by Wall St. Rank hold NBIX as of Q1 2018.

Shepherd Kaplan Krochuk reported no remaining Neurocrine Biosciences position as of Q1 2018 after selling out during the quarter.
Shepherd Kaplan Krochuk sold 4,094 Neurocrine Biosciences shares in Q1 2018, an estimated $318K.
Shepherd Kaplan Krochuk first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 19 quarters.
Shepherd Kaplan Krochuk's Neurocrine Biosciences position peaked at $1.69M in Q2 2015.
267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2018.

Based on Shepherd Kaplan Krochuk's 13F filing for Q1 2018, filed 11 May 2018.